Olmesartan/Amlodipine Hct (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide, the active ingredients in Olmesartan/Amlodipine HCT, are a combination antihypertensive presented as a tablet for oral use. It treats hypertension in adults, especially when single‑agent therapy does not achieve target blood pressure.

GNH USA supplies Olmesartan/Amlodipine HCT as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Amlodipine HCT is a fixed‑dose combination that addresses elevated blood pressure through three complementary mechanisms.

- Essential hypertension: lowers systolic and diastolic pressure when monotherapy is insufficient. - Uncontrolled hypertension: provides additional control in patients whose blood pressure remains above target despite other agents. - Hypertension requiring diuretic therapy: adds volume reduction and sodium‑water excretion to improve overall control.

The following adverse reactions have been reported with the combination product.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after the first dose. - Headache: mild to moderate intensity, often transient. - Peripheral edema: swelling of ankles or feet due to vasodilation. - Flushing: warm sensation and reddening of skin. - Fatigue: general tiredness without exertion. - Cough: occasional dry cough, more typical of ARB therapy.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips or throat, requiring emergency care. - Severe hypotension: marked drop in blood pressure leading to fainting. - Renal impairment: worsening kidney function, especially in patients with pre‑existing disease. - Electrolyte disturbances: hyponatremia, hypokalemia or hyperkalemia. - Hepatic dysfunction: abnormal liver enzymes or jaundice.

Before prescribing Olmesartan/Amlodipine HCT, clinicians should consider several safety aspects.

- Blood pressure monitoring: adjust therapy based on regular measurements. - Renal function assessment: evaluate serum creatinine and eGFR, especially in the elderly. - Electrolyte checks: monitor sodium and potassium levels due to the thiazide component. - Pregnancy and lactation: avoid use unless benefits clearly outweigh risks. - Concomitant potassium‑sparing agents: use with caution to prevent hyperkalemia. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Olmesartan/Amlodipine HCT may interact with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - ACE inhibitors: combined use increases risk of hyperkalemia and renal dysfunction. - Potassium supplements or potassium‑sparing diuretics: may cause dangerous hyperkalemia. - NSAIDs: can blunt antihypertensive effect and impair renal function. - Cyclosporine: may raise serum concentrations of amlodipine. - Lithium: increased lithium levels leading to toxicity.

Moderate Interactions (Monitor Closely): - Other diuretics: additive diuretic effect may cause dehydration. - Beta‑blockers: may enhance blood‑pressure lowering, requiring dose adjustments. - Antidiabetic agents: risk of hypoglycemia due to improved glucose control. - Strong CYP3A4 inhibitors: elevate amlodipine levels, monitor for edema. - CYP2C9 inhibitors: may affect hydrochlorothiazide metabolism, watch electrolytes.